Remus Pharmaceuticals Ltd
Incorporated in 2015, Remus Pharma Ltd is in the business of trading and export of API and Finished Formulations and in Technical consultancy services[1]
- Market Cap ₹ 967 Cr.
- Current Price ₹ 821
- High / Low ₹ 1,416 / 819
- Stock P/E 33.3
- Book Value ₹ 217
- Dividend Yield 0.06 %
- ROCE 23.2 %
- ROE 17.0 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
- Debtor days have improved from 130 to 63.6 days.
Cons
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 212 | 620 | |
| 185 | 575 | |
| Operating Profit | 28 | 46 |
| OPM % | 13% | 7% |
| 5 | 5 | |
| Interest | 0 | 1 |
| Depreciation | 1 | 2 |
| Profit before tax | 32 | 47 |
| Tax % | 18% | 19% |
| 26 | 38 | |
| EPS in Rs | 18.57 | 24.64 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 192% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 41% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -36% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 17% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Equity Capital | 1 | 6 |
| Reserves | 85 | 250 |
| 12 | 23 | |
| 159 | 154 | |
| Total Liabilities | 257 | 433 |
| 12 | 16 | |
| CWIP | 0 | 0 |
| Investments | 23 | 186 |
| 223 | 231 | |
| Total Assets | 257 | 433 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 4 | 7 | |
| -9 | -11 | |
| 24 | 6 | |
| Net Cash Flow | 19 | 2 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 197 | 64 |
| Inventory Days | 95 | 35 |
| Days Payable | 208 | 49 |
| Cash Conversion Cycle | 84 | 50 |
| Working Capital Days | 53 | 54 |
| ROCE % | 23% |
Documents
Announcements
-
Copy of Newspaper Publication
3 September 2025 - Notice of 10th AGM; annual report FY2024-25 dispatched; e-voting intimation; published Sep 03, 2025.
-
Record Date
2 September 2025 - Record date Sept 18, 2025 for final dividend Rs0.50/share; AGM Sept 25, 2025.
-
Shareholders meeting
2 September 2025 - AGM Sept 25, 2025; final dividend ₹0.50/share; MD reappointments; MD salary ₹2,29,20,000 p.a.
-
Analysts/Institutional Investor Meet/Con. Call Updates
2 September 2025 - Remus schedules virtual analyst/investor group meeting on 11 Sep 2025 at 4:00 PM IST.
-
Outcome of Board Meeting
29 August 2025 - Board reappointed MD Arpit Shah, WTD Roma Shah, Chairman Swapnil Shah, Non-exec Anar Shah for Jan16,2026–Jan15,2029; AGM approval pending.
Annual reports
Concalls
-
Aug 2025TranscriptNotesPPT
-
May 2025Transcript PPT
-
Nov 2024Transcript PPT REC
Busienss Overview:[1][2]
RPL and its group of companies specialize in marketing pharmaceutical products with expertise in Critical Care, Neurology, Cardiology, and Diabetic categories, and recently getting off-patent molecules in various dosage forms and in complex generics. Company gets finished pharmaceutical formulations manufactured on loan license or contract manufacturing